Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $11.00 USD
Change Today 0.00 / 0.00%
Volume 1.9M
IRWD On Other Exchanges
As of 8:10 PM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Peter M. Hecht Ph.D.

Co-Founder, Chief Executive Officer and Director,Ironwood Pharmaceuticals, Inc.
AgeTotal Calculated CompensationThis person is connected to 17 board members in 1 different organizations across 2 different industries.

See Board Relationships
As of Fiscal Year 2014


Dr. Peter M. Hecht, Ph.D. has been the Chief Executive Officer of Microbia, Inc (Ironwood Pharmaceuticals Inc.). since 1998. Dr. Hecht Co-Founded Ironwood Pharmaceuticals Inc. (Formerly Microbia, Inc.) in 1998. He serves on the Director's Council for the MIT Center for Cancer Research and the advisory board of Infante Sano. He also serves as Director at Microbia Precision Engineering, Inc. and Ironwood Pharmaceuticals Inc. He is an inventor of four of the patents licensed ...

Read Full Background

Corporate Headquarters*

301 Binney Street
Cambridge, Massachusetts 02142

United States

Phone: 617-621-7722
Fax: 617-494-0480

Board Members Memberships*

Co-Founder, Chief Executive Officer and Director


Stanford University
Stanford University
University of California Berkeley

Other Affiliations*

Annual Compensation*

Total Annual Compensation$100,000

Stock Options*

All Other Compensation$7,421
Exercised Options225,000
Exercised Options Value$3,242,250
Exercisable Options1,900,522
Exercisable Options Value$18,830,607
Unexercisable Options694,478
Unexercisable Options Value$1,036,643
Total Value of Options$24,879,100
Total Number of Options2,960,000

Total Compensation*

Total Annual Cash Compensation$107,421
Total Short Term Compensation$100,000
Other Long Term Compensation$7,421
Total Calculated Compensation$2,252,129
*Data is at least as current as the most recent Definitive Proxy.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IRWD:US $11.00 USD 0.00


Michael W. Aguiar Chief Executive Officer, President and Director
Theravance Inc.
Howard W. Robin Chief Executive Officer, President and Director
Nektar Therapeutics
Mark R. Baker J.D.Chief Executive Officer, Director and Member of Science & Strategy Committee
Progenics Pharmaceuticals, Inc.
Peter S. Greenleaf Chief Executive Officer and Director
Sucampo Pharmaceuticals, Inc.
A. J. Kazimi MBAFounder, Chairman, Chief Executive Officer and President
Cumberland Pharmaceuticals, Inc.
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IRONWOOD PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at